BTG PLC (LON:BTG) Rating Reaffirmed
BTG PLC (LON:BTG) stock “Hold” rating has been has reaffirmed by Analysts at Stifel in analysts report released on Monday, 14 December.
From a total of 6 analysts covering BTG PLC (LON:BTG) stock, 4 rate it a ”Buy”, 0 a “Sell”, and 2 a ”Hold”. This means that 67% of the ratings are positive. The highest target price is GBX 1100 while the lowest target price is GBX 550. The mean of all analyst targets is GBX 771 with a 23.06% above today’s (GBX 626.5) stock price. BTG PLC was the topic of 26 analyst reports since August 6, 2015 according to the firm StockzIntelligence Inc. Deutsche Bank maintained shares on December 14 with “Buy” rating. Stifel Nicolaus maintained shares with “Sell” rating and GBX 550 target share price in a report from an October 6. Jefferies maintained BTG stock in a recent report from November 12 with “Buy” rating. Finally, Panmure Gordon maintained the stock with “Buy” rating in a report issued on a November 10.
Approximately 115,883 shares of stock traded hands. BTG plc (LON:BTG) has declined 20.28% since May 15, 2015 and is downtrending. It has underperformed by 15.87% the S&P500.
BTG plc is a specialist healthcare company. The company has a market cap of 2.39 billion GBP. The Firm operates in three business divisions: Interventional Medicine (oncology, vascular and pulmonology products), Specialty Pharmaceuticals (antidote products) and Licensing (royalties from licensed assets). It has 53.46 P/E ratio. The Company’s Interventional Medicine segment offers a portfolio of interventional medicine products that are designed to advance the treatment of liver tumors, advanced emphysema, severe blood clots and varicose veins.
According to Zacks Investment Research, “B2Gold Corp. is involved in the exploration and development of gold. The company’s assets are situated in Nicaragua, Colombia, Namibia and Uruguay. B2Gold Corp. is headquartered in Vancouver, Canada.”